| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -95,247 |
| Depreciation of property and equipment | 196 |
| Stock-based compensation | 2,927 |
| Fair value of common stock issuable to related party | -7,769 |
| Change in fair value of participation right liability | 725 |
| Net accretion of premiums on marketable securities | 1,171 |
| Amortization of right-of-use assets | 220 |
| Prepaid expense and other currents assets | 4,365 |
| Other non-current assets | 398 |
| Accounts payble | 577 |
| Accrued compensation and benefits | 667 |
| Accrued research and development liabilities | 15,831 |
| Accrued professional services | 480 |
| Operating lease liabilities | 74 |
| Other accrued liabilities | -7 |
| Balances due to and from related parties | -62 |
| Net cash used in operating activities | -71,660 |
| Maturities of marketable securities | 128,976 |
| Purchases of marketable securities | 62,881 |
| Change in related party receivables related to cash pooling arrangement | 0 |
| Purchases of property and equipment | 533 |
| Net cash provided by (used in) investing activities | 65,562 |
| Proceeds from reverse recapitalization and pipe financing | 373,457 |
| Payment of deferred transaction costs | 11,691 |
| Issuance of series a redeemable convertible preferred stock | 0 |
| Issuance of series b redeemable convertible preferred stock, net of issuance costs | 22,222 |
| Contribution from bridgebio pharma | 0 |
| Net cash provided by financing activities | 383,988 |
| Net increase in cash, cash equivalents, and restricted cash | 377,890 |
| Cash and cash equivalents at beginning of period | 30,983 |
| Cash and cash equivalents at end of period | 408,873 |
BridgeBio Oncology Therapeutics, Inc. (BBOT)
BridgeBio Oncology Therapeutics, Inc. (BBOT)